STOCK TITAN
  1. Home
  2. News
  3. QRON

Qrons Announces Launch of its New Website Reflecting Expanded Neuronal Diseases Goals

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies is proud to announce the launch of its newly redesigned web site at https://www.qrons.com

The new site reflects Qrons' focus on extending its proprietary traumatic brain injury ("TBI") research to create a platform making use of synergic technologies to combat a broader range of neuronal diseases.

Jonah Meer, Qrons' Chief Executive Officer, commented, " We are thrilled to introduce our new website to educate the public about our expanded goal of leveraging our progress and proprietary knowledge to date with Israeli biotechnologies in a broader quest to treat neuronal diseases."

Ido Merfeld, Qrons' co-founder and President said, "We believe that our research discoveries may have the potential for broader applications beyond the treatment of TBIs if we are able to develop alongside new next generation technologies."

Liat Hammer, PhD, Qrons' Director of Research added "We hope to be able to collaborate with Israeli biotech startups whose technologies we believe can aid in the treatment of TBIs and other neuronal diseases."

The new website design will also provide Qrons greater flexibility in updating its website going forward.

About Qrons Inc.

Headquartered in New York City, with research conducted in Israel, Qrons is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. Qrons' approach is to seek to marshal and leverage the remarkable advances made in the fields of artificial intelligence (AI), machine learning (ML), molecular biology, stem cells and tissue engineering for deployment in the fight against neuronal diseases,. through development, acquisitions and investments. Please visit https://www.qrons.com

Forward Looking Statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, develop products, create alliances and attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contact:

Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

SOURCE: Qrons Inc.



View source version on accesswire.com:
https://www.accesswire.com/629341/Qrons-Announces-Launch-of-its-New-Website-Reflecting-Expanded-Neuronal-Diseases-Goals

Stock QRON logo
Qrons Inc.

OTC:QRON

QRON Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

QRON Latest News

Nov 20, 2023
Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program
Aug 23, 2023
Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Aug 14, 2023
Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Jan 20, 1970
Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and TBIs
Jul 20, 2023
Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries

QRON Stock Data

2.52M
3.51M
74.47%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Long Island City

About QRON

qrons inc., a preclinical stage biotechnology company, engages in developing stem cell synthetic hydrogel-based solutions to combat neuronal injuries, primarily focusing on traumatic brain injuries. its products candidates include qs100, an injury specific, 3d printable, implantable modified mesenchymal stem cells (mscs)-synthetic hydrogel to treat penetrating brain injuries; and qs200, an injectable mscs-synthetic hydrogel for the treatment of diffused injuries. qrons inc. has a license and research funding agreement with ariel university r&d co., ltd. for the development and commercialization of products for neuronal tissue regeneration and repair. the company was formerly known as biolabmart inc. and changed its name to qrons inc. in august 2017. qrons inc. was founded in 2016 and is based in new york, new york.